Get to know and reach out to the experts at Profil.

Short Bio

Dr. de Vries obtained board licenses in Internal Medicine and Endocrinology at the VU University Medical Centre, Amsterdam. He was a professor of Internal Medicine at the University of Amsterdam's Faculty of Medicine from 2016 to 2023.  Having joined Profil as of 2017, he maintains an outpatient clinic for people with diabetes one day per week. Dr. de Vries has been Principal Investigator in numerous clinical trials and has published more than 250 peer-reviewed scientific publications. He is a frequently invited speaker at international diabetes meetings, and has been a editorial board member of Diabetes Care, the Journal of Diabetes Science and Technology, and International Associate Editor of Diabetes Technology & Therapeutics.

Publications

Here you can find Hans' publications at or together with Profil.  For a full list of his other publications please click here.

• Klonoff, D. C., Bailey, T. S., Battelino, T., Cherñavvsky, D. R., DeVries, J. H., Mohan, V., Nichols, J. H., Rhee, C., Sacks, D. B., Tran, N. K., Scheideman, A. F., Shao, M. M., & Selvin, E. In Support of Venous Glucose as a Reference Matrix for Evaluating Continuous Glucose Monitoring Accuracy. Journal of diabetes science and technology 2026 Feb; doi: 10.1177/19322968261418711
  
• Heise, T., DeVries, J. H. Biosimilar insulins: Narrative review of the regulatory framework and registration studies. DIABETES OBES METAB 2025 Jul; 27 Suppl 5: 16-23. doi: 10.1111/dom.16320.
• DeVries, J. H., Heise, T. Once-weekly insulins. DIABETES TECHNOL THER 2025 Feb 6. doi: 10.1089/dia.2024.0653. Online ahead of print.
• Rothenbühler, M., Lizoain, A., Rebeaud, F., Perotte, A., Stoffel, M., DeVries, J. H. A prospective pilot study demonstrating noninvasive calibration-free glucose measurement. J DIABETES SCI TECHNOL 2025 Jan 29: 19322968251313811. doi: 10.1177/19322968251313811.
• Mather, K. J., Mari, A., Weerakkody, G., Heise, T., DeVries, J. H., Urva, S., Coskun, T., Milicevic, Z., Haupt, A., Thomas, M. K. Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis. DIABETES OBES METAB 2025; 27: 1507-1514.
• DeVries, J. H., Heckermann, S., Heise, T. Absence of a glucose-lowering effect in glucose clamp procedures with a long-acting insulin analogue. DIABETES OBES METAB 2024; 26: 6067-6069
• Andersen, G., Eloy, R., Heise, T., Gaudier, M., Megret, C., Seroussi, C., Chan, Y.-P., Soula, O., Riddle, M., DeVries, J. H. ADO09. a co-formulation of pramlintide and insulin A21G, lowers body weight versus insulin lispro in type 1 diabetes. DIABETES OBES METAB 26: 4639-4645.
• Mather, K. J., Mari, A., Heise, T., DeVries, J. H., Hua, M., Urva, S., Coskun, T., Haupt, A., Heine, R. J., Pratt, E., Thomas, M. K., Milicevic, Z. Effects of tirzepatide vs semaglutide on beta-cell function, insulin sensitivity, and glucose control during a meal test. J CLIN ENDOCRINOL METAB 2024 May 26. doi: 10.1210/clinem/dgae319. Online ahead of print.
• Jancev M, Vissers TACM, Visseren FLJ, van Bon AC, Serné EH, DeVries JH, de Valk HW, van Sloten TT. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetologia. 2024 May;67(5):798-810. doi: 10.1007/s00125-024-06107-6. Epub 2024 Feb 16. PMID: 38363342; PMCID: PMC10954850.
• DeVries JH, Irs A, Hillege HL. The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients. Eur Heart J. 2023 Oct 1;44(37):3492-3494. doi: 10.1093/eurheartj/ehad429. PMID: 37482673; PMCID: PMC10542624.
• Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., Milicevic, Z., Coskun, T. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. DIABETES CARE 2023; 46 (5): 998-1004
• Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, Kovatchev BP, Messer LH, Parkin CG, Ambler-Osborn L, Amiel SA, Bally L, Beck RW, Biester S, Biester T, Blanchette JE, Bosi E, Boughton CK, Breton MD, Brown SA, Buckingham BA, Cai A, Carlson AL, Castle JR, Choudhary P, Close KL, Cobelli C, Criego AB, Davis E, de Beaufort C, de Bock MI, DeSalvo DJ, DeVries JH, Dovc K, Doyle FJ, Ekhlaspour L, Shvalb NF, Forlenza GP, Gallen G, Garg SK, Gershenoff DC, Gonder-Frederick LA, Haidar A, Hartnell S, Heinemann L, Heller S, Hirsch IB, Hood KK, Isaacs D, Klonoff DC, Kordonouri O, Kowalski A, Laffel L, Lawton J, Lal RA, Leelarathna L, Maahs DM, Murphy HR, Nørgaard K, O'Neal D, Oser S, Oser T, Renard E, Riddell MC, Rodbard D, Russell SJ, Schatz DA, Shah VN, Sherr JL, Simonson GD, Wadwa RP, Ward C, Weinzimer SA, Wilmot EG, Battelino T. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2023 Mar 4;44(2):254-280. doi: 10.1210/endrev/bnac022. PMID: 36066457; PMCID: PMC9985411.
• Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., Milicevic, Z. Effects of tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. LANCET DIABETES ENDOCRINOL 10: 418-429, 2022
  
• Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, Ludwig B, Nørgaard K, Pettus J, Renard E, Skyler JS, Snoek FJ, Weinstock RS, Peters AL. The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2021 Nov;44(11):2589-2625. doi: 10.2337/dci21-0043. Epub 2021 Sep 30. PMID: 34593612.
• Herbrand T, Coester HV, Sansone R, Fischer A, Heiss C, Heise T, Kelm M, DeVries HJ. Improving the assessment of flow-mediated dilation through detection of peak time in healthy subjects and subjects with type 2 diabetes.
  ANGIOLOGY 2020 Dec 30. doi: 10.1177/0003319720984884. Online ahead of print
  
• Andersen G, Meiffren G, Famulla S, Heise T, Ranson A, Seroussi C, Eloy R, Gaudier M, Charvet R, Chan Y-P, Soula O, DeVries JH.
  ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D). 
  DIABETES OBES METAB 2020 Dec 18. doi: 10.1111/dom.14302. Online ahead of print. 
  

Browse Profil's list of publications to see our other publications.